2021 Short Course - A Clinician’s Perspective on Obesity: Syndromic and Non-Syndromic Causes, Treatment and Challenges-A Clinician’s Perspective on Obesity

Video Transcription

Video Summary

The video content discussed non-syndromic forms of monogenic obesity, genetic disorders such as leptin deficiency, leptin receptor deficiency, POMC, PCSK1, and MC4R mutations, and the emerging mechanism-based therapies for these disorders. It highlighted the association of behavioral features with genetic obesity disorders and the potential benefits of genetic testing in providing targeted therapies. It also mentioned two cases where genetic testing confirmed the diagnosis of 16p11.2 deletion syndrome and MC4R-related obesity, leading to appropriate management and support. The importance of multidisciplinary evaluation and management in the Genetics Obesity Clinic was emphasized. <br /><br />In addition to the discussion on genetic obesity, the video also mentioned FDA-approved medications such as Belvique (Lorcaserin) and other medications like Orlistat and Phentermine-Topiramate for the treatment of obesity. It mentioned ongoing clinical trials for new treatments, including set-nadisant for Prader-Willi syndrome and RM493 for MC4R deficiency obesity. These treatments showed promising results in reducing hyperphagia, promoting weight loss, and improving other symptoms. However, it noted that these treatments are still in the experimental stages and may not be widely available yet.<br /><br />Overall, the video highlighted the potential of targeted therapies and the need for further research and clinical trials in understanding and treating genetic obesity. It emphasized the significance of a comprehensive approach in managing patients with genetic obesity and the hope for more effective treatments in the future.

Keywords

non-syndromic forms of monogenic obesity

genetic disorders

leptin deficiency

leptin receptor deficiency

POMC mutations

PCSK1 mutations

MC4R mutations

mechanism-based therapies

behavioral features

genetic testing

16p11.2 deletion syndrome

MC4R-related obesity

multidisciplinary evaluation

FDA-approved medications

ongoing clinical trials